Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.

MLA

Kurimchak, Alison M., et al. “Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.” Cell Reports, vol. 16, no. 5, Aug. 2016, pp. 1273–86. EBSCOhost, https://doi.org/10.1016/j.celrep.2016.06.091.

APA

Kurimchak, A. M., Shelton, C., Duncan, K. E., Johnson, K. J., Brown, J., O’Brien, S., Gabbasov, R., Fink, L. S., Li, Y., Lounsbury, N., Abou-Gharbia, M., Childers, W. E., Connolly, D. C., Chernoff, J., Peterson, J. R., & Duncan, J. S. (2016). Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Reports, 16(5), 1273–1286. https://doi.org/10.1016/j.celrep.2016.06.091

Chicago

Kurimchak, Alison M, Claude Shelton, Kelly E Duncan, Katherine J Johnson, Jennifer Brown, Shane O’Brien, Rashid Gabbasov, et al. 2016. “Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.” Cell Reports 16 (5): 1273–86. doi:10.1016/j.celrep.2016.06.091.